Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOBILE: Monthly vs Daily Ibandronate in Postmenopausal Osteoporosis
NCT00048061Phase 3Completed
- Sponsor
- Roche
- Start
- Apr 2002
- Primary completion
- Dec 2004
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of ibandronate in postmenopausal osteoporosis (4 arms), sponsored by Roche. Primary endpoint: Relative Change From Baseline at One Year (12 Months) in Mean Lumbar Spine (L2 - L4) Bone Mineral Density. Started Apr 2002; status: completed.
02
Drugs
ibandronate
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT00048061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00048061.